FC
TVTX icon

FORA Capital’s Travere Therapeutics TVTX Stock Holding History

FORA Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
+27,289
New +$1.21M 0.11% 183
2026
Q1 		– Sell
-8,023
Closed -$358K – 604
2025
Q4 		$358K Buy
+8,023
New +$261K 0.04% 346
2020
Q4 		– Sell
-2,387
Closed -$44K – 1146
2020
Q3 		$44K Sell
2,387
-5,679
-70% -$110K 0.03% 457
2020
Q2 		$165K Buy
8,066
+4,520
+127% +$72K 0.06% 392
2020
Q1 		$52K Buy
+3,546
New +$53.4K 0.01% 764

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FORA Capital's TVTX Position: Q2 2026 in Review

FORA Capital opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 27,289 shares worth $1.55M. The stake represents 0.11% of the portfolio and ranks #183 among its holdings. This is a return to the name: FORA Capital previously reported a position in TVTX as recently as Q4 2025.

FORA Capital first reported a position in TVTX in Q1 2020 and has held it in 5 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • FORA Capital held 27,289 shares of Travere Therapeutics worth $1.55M as of Q2 2026.
  • Travere Therapeutics was a new FORA Capital position in Q2 2026.
  • Travere Therapeutics made up 0.11% of FORA Capital's portfolio in Q2 2026, its #183 holding.
  • FORA Capital first reported a position in Travere Therapeutics in Q1 2020 and has held it in 5 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.